Nexalin Technology, Inc. filings document a Nasdaq-listed medical technology issuer developing DIFS™ neurostimulation products for mental-health and neurological indications. Its Form 8-K reports cover material agreements for the HALO Clarity pivotal study, Regulation FD clinical-trial updates, Nasdaq listing-compliance notices, equity distribution and at-the-market offering arrangements, and executive employment and equity-compensation matters.
The filing record also documents the company’s common stock and prior warrant securities, including the expiration and delisting of warrants through a Form 25 process. Disclosures identify Nexalin as an emerging growth company and describe governance, capital-structure and corporate-status matters relevant to its public-company reporting.